Abstract
Ovarian clear cell adenocarcinoma (OCCA) is known to have a worse prognosis than ovarian serous adenocarcinoma due to its poor response to conventional platinum-based chemotherapy. Idiopathic thrombocytopenic purpura (ITP), which usually reveals severe thrombocytopenia, is a common autoimmune disorder. However, to date very few cases of ovarian cancer associated with ITP have been reported in the literature. We report a case of a 57-year-old woman who developed OCCA 14 years after the diagnosis of ITP. The patient presented with abdominal distention and mild tenderness. We performed the operation with high-dose immunoglobulin therapy preoperatively, and diagnosed OCCA. Postoperatively, six cycles of cytotoxic chemotherapy with irinotecan hydrochloride plus cisplatin were performed every 4–5 weeks without thrombocytopenia. We conclude that combination chemotherapy with irinotecan hydrochloride plus cisplatin is useful for a case of OCCA associated with ITP.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sugiyama T, Yakushiji M, Kamura T, Japan CPT-11 Study Group et al (2002) Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology 63:16–22
Peffault de Latour R, Des Guetz G, Laurence V et al (2004) Breast cancer associated with idiopathic thrombocytopenic purpura: a single center series of 10 cases. Am J Clin Oncol 27:333–336
Chehal A, Taher A, Seoud M et al (2003) Idiopathic thrombocytopenic purpura and ovarian cancer. Eur J Gynaecol Oncol 24:539–540
Tarraza HM, Carroll R, De Cain M et al (1991) Recurrent ovarian carcinoma: presentation as idiopathic thrombocytopenic purpura and a splenic mass. Eur J Gynaecol Oncol 12:439–443
George JN, Woolf SH, Raskob GE et al (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88:3–40
Cheng Y, Wong RS, Soo YO et al (2003) Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 349:831–836
Ozols RF, Bundy BN, Greer BE, Gynecologic Oncology Group et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194–3200
Takakura S, Takano M, Takahashi F, Japanese Gynecologic Oncology Group et al (2010) Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer 20:240–247
Conflict of interest
The authors declare that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Wakana, K., Yasugi, T., Nako, Y. et al. Successful surgical treatment and chemotherapy for ovarian cancer in a patient with idiopathic thrombocytopenic purpura. Int J Clin Oncol 16, 447–449 (2011). https://doi.org/10.1007/s10147-010-0149-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-010-0149-3